International Stroke Conference 2025  /  Late-Breaking Science Posters  /  Impact of Blood Pressure during Thrombectomy in Basilar Artery Occlusion based on Collateral Circulation Status
Logo

American Heart Association

  2
  0

Final ID: LBP7

Impact of Blood Pressure during Thrombectomy in Basilar Artery Occlusion based on Collateral Circulation Status

Abstract Body: Background and Objectives
We investigated the relationship between intraprocedural blood pressure (BP) and clinical outcomes in patients with basilar artery occlusion (BAO) undergoing endovascular treatment (EVT), exploring if it is modifiable by collateral status.
Methods
Patient data from the ATTENTION (Endovascular Treatment for Acute Basilar Artery Occlusion) randomized trial were analyzed for those undergoing BAO that received EVT. Intraprocedural BP data were extracted, with collateral status assessment using the Basilar Artery on Computed Tomography Angiography (BATMAN) score (BATMAN ≥ 7 favorable collateral status, < 7 unfavorable). BP parameter effects on functional outcomes were assessed using multivariable logistic regression analysis, including a multiplicative interaction term model for assessing BP parameter modification by collateral status on outcomes. The primary outcome was favorable outcome defined by a modified Rankin Scale (mRS) score of 0-3 at 90 days.
Results
There were 212 patients included. Multivariable analysis revealed greater minimum mean arterial pressure (MAP) and systolic blood pressure (SBP) per 10 mmHg was associated with favorable outcomes (aOR 1.45, 95%CI 1.02-2.09; aOR 1.31, 95%CI 1.03-1.67). MAP < 80 mmHg (aOR 0.52, 95% CI 0.27-0.96) or > 110 mmHg (aOR 0.52, 95% CI 0.28-0.95) were associated with decreased probability of favorable outcome. Significant interactions were observed between collateral status and BP parameters (minimum SBP, SD of MAP and SBP, and MAP < 80 mmHg) in relation to favorable outcome (corrected Pinteraction < 0.05). In patients with unfavorable collateral status, increased minimum SBP was associated with a greater favorable outcome probability (aOR 3.93, 95%CI 1.92-10.40), while SD increases of MAP and SBP, and MAP < 80 mmHg were associated with decreased probability (aORs 0.05, 95%CI 0.01-0.32; 0.07, 95%CI 0.01-0.32; and 0.04, 95%CI 0.00-0.21, respectively). These relationships were not observed in patients with favorable collaterals.
Conclusion
In patients with BAO undergoing EVT with unfavorable collateral status, intraprocedural MAP < 80 mmHg was associated with worse clinical outcomes, indicating the importance of close surveillance and management of intraprocedural BP during EVT.
  • Luo, Cong  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Michel, Patrik  ( Lausanne University Hospital , Lausanne , Swaziland )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Raul, Nogueira  ( University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , United States )
  • Liu, Xinfeng  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Hu, Wei  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Nguyen, Thanh  ( Boston Medical Center , Boston , Massachusetts , United States )
  • Li, Rui  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Tao, Chunrong  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Jing, Xiaozhong  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Xu, Pengfei  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Wang, Li  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Wang, Anmo  ( The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei , China )
  • Abdalkader, Mohamad  ( Boston Medical Center , Boston , Massachusetts , United States )
    • Author Disclosures:
    Cong Luo: DO NOT have relevant financial relationships | Patrik Michel: DO have relevant financial relationships ; Research Funding (PI or named investigator):Swiss National Science Foundation:Active (exists now) ; Research Funding (PI or named investigator):Faculty of Biology and Medicine of the University of Lausanne:Past (completed) ; Research Funding (PI or named investigator):Swiss Heart Foundation:Active (exists now) | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Nogueira Raul: No Answer | Xinfeng Liu: DO NOT have relevant financial relationships | Wei Hu: DO NOT have relevant financial relationships | Thanh Nguyen: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):American Stroke Association:Active (exists now) ; Advisor:Aruna Bio:Past (completed) ; Advisor:Brainomix:Active (exists now) | Rui Li: No Answer | Chunrong Tao: No Answer | Xiaozhong Jing: No Answer | Pengfei Xu: No Answer | Li Wang: No Answer | Anmo Wang: DO NOT have relevant financial relationships | Mohamad AbdalKader: No Answer
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Late-Breaking Science Posters

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A Bridge from Sweet to Sour: A Case of Recurrent Myocardial Stunning in Diabetic Ketoacidosis

Satish Vikyath, Pargaonkar Sumant, Slipczuk Leandro, Schenone Aldo, Maliha Maisha, Chi Kuan Yu, Sunil Kumar Sriram, Borkowski Pawel, Vyas Rhea, Rodriguez Szaszdi David Jose Javier, Kharawala Amrin, Seo Jiyoung

A pilot study of an intervention for self-management of blood pressure among refugees fleeing war and resettled in the United States

Behnam Rawnaq, Godino Job, Celis Deisy, Anderson Cheryl, Al-rousan Tala

More abstracts from these authors:
Tenecteplase as the New Standard for Intravenous Thrombolysis

Turc Guillaume, Tsivgoulis Georgios, Alamowitch Sonia, Siegler James, Roaldsen Melinda, Michel Patrik

Glucagon-Like Peptide-1 Receptor Agonist in Large Vessel Occlusion Stroke Treated by Reperfusion Therapy – a randomized trial

Wang Hao, Ko Ho, Leung Thomas, Hu Wei, Che Fengyuan, Ip Bonaventure Yiu Ming

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)